

20**Detection of Reactive Oxygen Species and Nitric Oxide
in Vascular Cells and Tissues***Comparison of Sensitivity and Specificity***Hua Cai, Sergey Dikalov, Kathy K. Griendling, and David G. Harrison****Summary**

Reactive oxygen and nitrogen species are thought to contribute to pathogenesis of many cardiovascular diseases including hypertension, atherosclerosis, restenosis, heart failure, and diabetic vascular complications. Some of these reactive oxygen species also play an important role in vascular signaling. In this chapter, we describe various techniques that we have successfully employed to reliably measure superoxide and hydrogen peroxide. Because reactive oxygen species are capable of rapidly inactivating nitric oxide and because endothelial function characterized by nitric oxide bioavailability is an important indicator of vascular health, we have also included novel techniques capable of directly measuring nitric oxide radical from vascular cells and tissues.

Key Words: Reactive oxygen species; Nitric oxide; Vascular smooth muscle cells; Methods.

1. Introduction

Increased production of reactive oxygen species outstripping endogenous anti-oxidant defense systems has been referred to as oxidant stress, which in turn contributes to pathogenesis of many cardiovascular diseases including hypertension, atherosclerosis, restenosis, heart failure, and diabetic vascular complications (1–4). In mammalian cells, potential enzymatic sources of reactive oxygen species include the mitochondrial electron transport chain, the arachidonic acid metabolizing enzymes lipoxygenase and cyclooxygenase,

From: *Methods in Molecular Medicine, Vol. 000: Vascular Biology Protocols*
Edited by: N. Sreejayan and J. Ren © Humana Press Inc., Totowa, NJ

01 the cytochrome P450s, xanthine oxidase, NAD(P)H oxidases, uncoupled nitric
02 oxide synthase (NOS), peroxidases, and other hemoproteins. Among biolog-
03 ically relevant and abundant reactive oxygen species, superoxide ($O_2^{\bullet-}$) and
04 its dismutation product hydrogen peroxide (H_2O_2) appears most important in
05 vascular signaling (1–4). On the contrary, recent studies suggest that $O_2^{\bullet-}$ and
06 H_2O_2 may have differential signaling roles in the vasculature under various
07 conditions (5–7). Both can be simultaneously produced by xanthine oxidase
08 and some recently identified reduced nicotinamide dinucleotide (phosphate)
09 (NAD(P)H) oxidases (6). Thus, production of H_2O_2 may correlate with
10 formation of $O_2^{\bullet-}$. It does not, however, always reflect rate of $O_2^{\bullet-}$ generation,
11 because other systems such as mitochondria or uncoupled eNOS produce $O_2^{\bullet-}$
12 solely. The efficacy of $O_2^{\bullet-}$ dismutation into H_2O_2 is affected by the abundance
13 of intracellular superoxide dismutase (SOD) and small reducing molecules
14 such as glutathione. Herein, we describe various techniques that we have
15 successfully employed to reliably measure $O_2^{\bullet-}$ or H_2O_2 differentially. Because
16 reactive oxygen species are capable of rapidly inactivating nitric oxide (NO^{\bullet})
17 and endothelial function characterized by NO^{\bullet} bioavailability is an important
18 indicator of vascular health (1,2), this review also discusses novel techniques
19 capable of directly measuring NO^{\bullet} from vascular cells and tissues.

20 Comprehensive reviews on methodologies detecting reactive oxygen species
21 are available (8,9). This chapter instead primarily focuses on simplified
22 and user-friendly experimental protocols and technical notes that are practi-
23 cally applicable to vascular biological studies. Taking into consideration the
24 complexity of the biology of reactive oxygen species and limitations of
25 individual techniques, it is generally recommended that reactive oxygen species
26 should be measured with at least two different assays.

27 **1.1. Superoxide Analysis**

28
29 Though superoxide ($O_2^{\bullet-}$) is very short lived, largely cell impermeable and
30 less likely to serve as a dominant signaling intermediate compared to other
31 reactive oxygen species including H_2O_2 and NO^{\bullet} it remains the precursor
32 of many biologically relevant and important reactive oxygen species. More
33 importantly, it rapidly reacts with NO^{\bullet} to inactivate NO^{\bullet} in a diffusion-limited
34 fashion, which in turn leads to NO^{\bullet} deficiency and endothelial dysfunction,
35 hallmarks of many vascular diseases, including hypertension, atherosclerosis,
36 and diabetic vascular complications (1–4). Many assays have been used to
37 detect $O_2^{\bullet-}$ in test tubes, with cultured cells or intact blood vessels. Only
38 the assays with which we are personally experienced are discussed in this
39 chapter.




Fig. 2. Measurements of intracellular $O_2^{\bullet-}$ by dihydroethidium–HPLC. Inset shows typical HPLC diagram illustrating the formation $O_2^{\bullet-}$ -specific adduct, oxyethidium. Treatment of rat aortic smooth muscle cells (RASMC) with polyethylene glycol (PEG)–superoxide dismutase (SOD) (18-h incubation with 25 U/ml) strongly inhibited oxyethidium formation in angiotensin II-stimulated (100 nmol/l, 4 h) cells. Data are presented as mean \pm SEM. * $p < 0.01$ versus RASMC, ** $p < 0.01$ versus angiotensin II.

used to detect $O_2^{\bullet-}$ formation from angiotensin II-stimulated or oscillatory shear stress-stimulated endothelial cells (16,17) or coronary artery homogenates of heart failure patients (18). ESR has a detection limit of approximately 1 nmol/L (10^{-9} M) for $O_2^{\bullet-}$, representing one of the most sensitive, quantitative, and characteristic means of measuring $O_2^{\bullet-}$.

1.1.3. Cytochrome C Reduction Assay

Traditionally, in the pre-ESR era, the cytochrome C reduction assay was considered the “gold standard” for detection of $O_2^{\bullet-}$. The rate constant for $O_2^{\bullet-}$ reduction of ferricytochrome C is approximately 1.5×10^5 /M/s (8), allowing relatively sensitive detection of $O_2^{\bullet-}$.

1.1.4. Lucigenin Assay

Lucigenin at low concentrations ($< 5 \mu\text{M}$) has been shown to detect $O_2^{\bullet-}$ without background noise derived from its own redox cycling (9). The experimental procedure, precautions, advantages, and potential caveats of this assay have been comprehensively reviewed previously by Munzel et al. (9). Lucigenin

01 remains a valid method for $O_2^{\bullet-}$ production, when appropriate experimental
02 procedures are used, as clearly described in the abovementioned review.

03 **1.2. Detection of Hydrogen Peroxide**

05 Emerging evidence has demonstrated a critical role of H_2O_2 in vascular
06 signaling (19–20). Different from the very short-lived $O_2^{\bullet-}$, H_2O_2 is more
07 stable and freely diffusible among adjacent cells. Its production can be rapidly
08 increased through agonist-provoked activation of vascular NAD(P)H oxidases.
09 Uniquely, H_2O_2 also amplifies its own production and modulates endothelial
10 function through complex mechanisms (19,20). These properties of H_2O_2 make
11 it an ideal signaling molecule. Hydrogen peroxide levels in vascular cells and
12 tissues can be monitored by the following assays.

13 **1.2.1. Dichlorofluorescein Fluorescent Assay**

14
15 The chemical basis of the assay is that upon entry into cells, 2'-7'-
16 dichlorodihydrofluorescein diacetate (DCFH-DA; Molecular Probes, Eugene,
17 OR, USA) is cleaved by intracellular esterases to form DCFH, which is then
18 oxidized by peroxides to highly fluorescent DCF.

19 **1.2.2. Amplex Red Assay**

20
21 Amplex Red (chemical name *N*-acetyl-3,7-dihydroxyphenoxazine) is a
22 commercial compound from Molecular Probes. It reacts with extracellular H_2O_2
23 in the presence of peroxidase to form the highly fluorescent substance resorufin.

24 **1.2.3. Hydrogen Peroxide Electrode**

25
26 Liu and Zweier (21) previously reported that a *o*-phenylenediamine
27 dihydrochloride (*o*-PD)-coated platinum microelectrode is capable of detecting
28 H_2O_2 specifically and quantitatively from activated neutrophils. Although
29 the specificity of the electrode is well characterized in the study and it
30 detected 6–8 $\mu\text{mol/l}$ H_2O_2 released from activated neutrophils, it remains
31 unclear whether it is able to detect the small fraction of H_2O_2 released from
32 vascular cells that have much lower production of H_2O_2 .

33 **1.3. Detection of Nitric Oxide Radical**

34
35 It has been challenging to detect nitric oxide radical (NO^{\bullet}) directly from
36 biological samples. Earlier studies mostly assessed NO^{\bullet} “production” through
37 indirect measurements of NO^{\bullet} synthase activity using the *L*-arginine conversion
38 assay or NO^{\bullet} metabolites nitrite and nitrate using the Griess reagent. These
39 assays, however, only reflect the enzyme activity or cumulative NO^{\bullet} production,
providing no information on actual bioavailable NO^{\bullet} . Studies in the past few

01 years have shown that a NO[•]-selective electrode and ESR represent specific
02 and quantitative assays for detection of functional NO[•].

03 1.3.1. NO[•]-Specific Microelectrode

04
05 Friedemann and colleagues (22) previously showed that nafion and *o*-PD-
06 coated carbon electrode can directly detect NO[•]. We adapted this method
07 for direct NO[•] detection from porcine endocardium with and without atrial
08 fibrillation (23). These studies showed that the NO[•]-selective electrode is able
09 to detect NO[•] in the low micromolar range.

10 1.3.2. ESR with NO[•]-Specific Spin Traps

11
12 Several iron compounds have been used to specifically trap NO[•], including
13 dithiocarbamate (DTC), N-methylglucamine dithiocarbamate (MGD), and
14 diethyldithiocarbamate (DETC) (24). Although MGD is useful for extracel-
15 lular detection of NO[•] (25–27), iron-DETC is particularly useful for detection
16 of NO[•] in the cellular lipid membrane (28,29). The following protocols are
17 described for both iron-MGD and iron-DETC.

18 2. Materials

19 2.1. Detection of Superoxide

20 2.1.1. DHE Staining—Microscopic Method

- 21 1. Endothelial cells, vascular smooth muscle cells, or isolated vascular segments.
- 22 2. Tissue Freezing Medium (Triangle Biomedical Sciences, Durham, NC, USA).
- 23 3. Cover slips and slides (Fisher Scientific, Pittsburgh, PA).
- 24 4. DHE (Molecular Probes) stock solution: 2–5 mM dissolved in dimethylsulfoxide,
25 prepare fresh in dark.
- 26 5. Phosphate-buffered saline (PBS).
- 27 6. Mounting media: Prolong anti-fade (Molecular Probes).
- 28 7. Fluorescent microscope.
- 29 8. Tissue Freezing Medium (Triangle Biomedical Sciences).

30 2.1.2. DHE Staining—HPLC Method

- 31 1. Endothelial cells, vascular smooth muscle cells, or isolated vascular segments.
- 32 2. Modified Kreb's/4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
33 buffer: 99.0 mM NaCl, 4.69 mM KCl, 1.87 mM CaCl₂, 1.20 mM MgSO₄, 25 mM
34 NaHCO₃, 1.03 mM K₂HPO₄, 20 mM sodium-HEPES, and 11.1 mM D-glucose
35 (pH 7.35) containing 25 or 50 μM DHE Tissue Freezing Medium (Triangle
36 Biomedical Sciences).
- 37 3. Acetonitrile (37–47%).
- 38 4. Trifluoroacetic acid (0.1%).
- 39

- 01 5. Xanthine oxidase (5 mU/ml).
- 02 6. Xanthine (10–100 μ M).
- 03 7. Tissue Grinder (Fisher Scientific).
- 04 8. Syringe filter, 0.22 μ m.
- 05 9. HPLC equipped with a sensitive fluorescent detector (Beckman Coulter, Fullerton,
06 CA; Shimadzu by Fisher Scientific, Pittsburgh, PA).
- 07 10. C-18 reverse phase column (Nucleosil 250, 4.5 mm; Sigma-Aldrich, St. Louis,
08 MO, USA).

09 2.1.3. ESR

- 10 1. Endothelial or vascular smooth muscle cells.
- 11 2. Modified Krebs/HEPES buffer (*see Subheading 2.1.1.2.*).
- 12 3. Cyclic hydroxylamine CPH or 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethyl-
13 pyrrolidine (CMH) stock solution (10 mM) (Alexis Biochemicals, San Diego, CA,
14 USA) in modified Krebs's/HEPES buffer containing metal chelator, 25–50 μ M
15 deferoximine, and 3.5 μ M DETC. This stock solution should be de-oxygenated by
16 nitrogen gas continuously to maintain low background oxidation of the spin traps.
- 17 4. Lysis buffer containing protease inhibitors: 50 mM Tris–HCl buffer, pH 7.4,
18 containing 0.1 mM ethylenediamine tetraacetic acid (EDTA), 0.1 mM ethylene
19 glycol tetraacetic acid (EGTA), 1 mM phenylmethyl sulfonyl fluoride, 2 μ M
20 bestatin, 1 μ M pepstatin, and 2 μ M leupeptin.
- 21 5. NADPH (0.2 mM).
- 22 6. Xanthine (0.1 mM).

23 2.1.4. Cytochrome C Reduction Assay

- 24 1. Endothelial cells or vascular cells.
- 25 2. Acetylated cytochrome C: 50 μ M.
- 26 3. Potassium phosphate buffer pH 7.4 (KPi buffer): 50 mM K_2HPO_4 and 50 mM
27 KH_2PO_4 , pH 7.8.
- 28 4. Catalase 1 U/ μ l.
- 29 5. SOD (1 U/ μ l).
- 30 6. Fluorescent plate reader.

31 2.2. Detection of Hydrogen Peroxide

32 2.2.1. Dichlorofluorescein Fluorescent Assay

- 34 1. Cultured cells.
- 35 2. Dichlorofluorescein (DCF): 30 μ M.
- 36 3. Fluorescent plate reader.

37 2.2.2. Amplex Red Assay

- 38 1. Amplex Red Assay kit from Molecular Probes.
- 39

2.3. Detection of Nitric Oxide Radical

2.3.1. NO[•]-Specific Microelectrode

1. Carbon fiber electrodes (100 μm length and 30 μm outer diameter; Word Precision Instruments, Sarasota, FL, USA).
2. *o*-PD solution (in 0.1 M PBS with 100 μM ascorbic acid).
3. Nafion (5% in aliphatic alcohols; Sigma-Aldrich).
4. Modified Krebs's/HEPES buffer.
5. Axopatch 200B amplifier (Axon Instruments, Union City, CA, USA).
6. Silver/silver chloride reference electrode.

2.3.2. Iron-DETC for Trapping of NO[•]

1. Culture endothelial cells.
2. Saline (0.9% NaCl).
3. Fe²⁺(DETC)₂: FeSO₄·7H₂O, 4.45 mg/10 ml for 1.6 mmol/l stock and DETC, 7.21 mg/10 ml for 3.2 mmol/l stock.
4. PBS.
5. Modified Krebs's/HEPES buffer.
6. Ferrous sulfate (4 mM).
7. *N*-methyl-D-glucamine dithiocarbamate MGD (20 mM).

3. Methods

3.1. Detection of Superoxide Anion

3.1.1. DHE Assay—Microscopic Method (See **Notes 1 and 2**)

1. Culture endothelial cells or vascular smooth muscle cells on glass cover slips in six-well plates. Alternatively, embed freshly isolated vascular segments (2 mm) in tissue freezing medium, section to 30 μm, and mount on cover slips.
2. Dilute DHE in PBS to final concentration of 2–5 μmol/l. Add 200 μl drops of DHE–PBS solution on cell monolayer or tissue section and incubate at 37°C in dark for 30 min.
3. Rinse off excess DHE with PBS twice, drip off excess liquid, and mount cover slips to microscopic slides using mounting media.
4. Capture images immediately with a fluorescent microscope at excitation and emission wavelengths of 520 and 610 nm, respectively.
5. If drug treatment is desired, pre-incubate with cells or tissue sections prior to addition of DHE.

3.1.2. DHE Assay—HPLC Method (See **Notes 3 and 4**)

1. Treat endothelial cells or 2-mm vessel segments (*see Note 4*) with desired agonists and incubate in modified Krebs's/HEPES buffer at 37°C in dark for 15 min–1 h.

- 01 2. At end of the incubation, collect cells by gentle scraping, homogenize cells or vessel
 02 segments in chilled methanol using a Tissue Grinder, and filter suspensions through
 03 a 0.22- μm syringe filter.
 04 3. Analyze the supernatant using a HPLC equipped with a C-18 reverse phase column
 05 and a sensitive fluorescent detector, at excitation and emission wavelengths of 480
 06 and 580 nm, respectively. A gradient of acetonitrile from 37 to 47% over 23 min at
 07 a flow rate of 0.5 ml/min mixed with 0.1% trifluoroacetic acid is used as solvent to
 08 separate DHE, ethidium, and oxyethidium.
 09 4. Calibration of oxyethidium formation from DHE is obtained by incubation of
 10 DHE with xanthine oxidase (5 mU/ml) and increasing concentrations of xanthine
 11 (10–100 μM).
 12 5. A representative HPLC–DHE assay of $\text{O}_2^{\bullet-}$ production from angiotensin II-
 13 stimulated vascular smooth muscle cells is presented in **Fig. 3**.

14 3.1.3. ESR with Superoxide-Specific Spin Traps (See **Notes 5 and 6**)

- 15 1. Culture endothelial or vascular smooth muscle cells to confluence on 100-mm Petri
 16 dishes. Wash off media and collect cells in modified Kreb's/HEPES buffer.
 17 2. Gently scrape cells off culture dish and collect in ice-cold Kreb's/HEPEs buffer.
 18 After centrifuging at 500 g for 10 min at 4°C, re-suspend cell pellets in freshly
 19 prepared deferoxamine-containing Kreb's/HEPEs buffer. Usually a density of
 20 1×10^6 cells/ $10 \mu\text{l}$ is desired.
 21 3. Mix in an Eppendorf tube 10 μl cell suspension, 80 μl of Kreb's/HEPEs buffer, and
 22 10 μl CPH or CMH stock solution (final concentration 1 mM).
 23 4. Immediately transfer sample into glass capillaries and load capillaries into appro-
 24 priate ESR cavity for 10-min time scan.




Fig. 3. Nitron spin traps and formation of $\text{O}_2^{\bullet-}$ -derived radical adducts.

01 3.1.3.1. ANALYSIS OF $O_2^{\bullet-}$ IN MEMBRANE PREPARATIONS OF CELLS OR TISSUES
02 TO ASSESS NADPH OXIDASE AND XANTHINE OXIDASE ACTIVITY

- 03 1. Homogenize cultured vascular endothelial cells, smooth muscle cells, or vessel
04 segments in lysis buffer using a Tissue Grinder.
- 05 2. Centrifuge samples at 750 g at 4°C for 10 min. Remove supernatant and centrifuge
06 at 30,000 g at 4°C for 30 min.
- 07 3. Resuspend membrane pellet in 150 μ l lysis buffer and measure protein concentration
08 using the Bradford method.
- 09 4. Prepare cyclic hydroxylamine CPH or CMH stock solution as described above.
- 10 5. Mix in an Eppendorf tube with 10 μ l membrane preparation: 80 μ l of Kreb's/HEPEs
11 buffer and 10 μ l of the CPH stock solution (1 mM). Activity of NADPH oxidase
12 can be determined by adding NADPH (0.2 mM) as the substrate, whereas activity
13 of xanthine oxidase is determined by adding xanthine (0.1 mM).
- 14 6. Immediately transfer membrane-spin trap mix into glass capillaries and load capil-
15 laries into appropriate ESR cavity for 10-min time scan. Use the following ESR
16 settings described below:

17 Bruker EMX. Field sweep, 50 G; microwave frequency, 9.78 GHz; micro-
18 wave power, 20 mW; modulation amplitude, 2 G; conversion time, 1312 ms;
19 time constant, 656 ms; 512 points resolution; and receiver gain, 1×10^5 .

20 Miniscope 200. Biofield, 3350 G; field sweep, 40 G; microwave frequency,
21 9.78 GHz; microwave power, 20 mW; modulation amplitude, 3 G; 4096 points
22 resolution; and receiver gain, 500.

23
24 3.1.4. Cytochrome C Reduction Assay (See **Notes 7 and 8**)

- 25
26 1. Culture endothelial cells or vascular smooth cells in 6-well or 12-well plates or
27 prepare vessel segments (3 \times 2 mm rings). Wash off media or blood residues using
28 warm PBS.
- 29 2. Incubate cells or tissues with acetylated cytochrome C (50 μ M) in KPI buffer
30 containing 1 U/ μ l catalase (to prevent re-oxidation of reduced cytochrome
31 C by H_2O_2) in the dark at 37°C for 1 h. An identical set of samples is
32 incubated in the presence of SOD (1 U/ μ l) for subtraction of the SOD-inhibitable
33 signal.
- 34 3. Transfer 200 μ l post-incubation supernatant to a fresh 96-well plate and read the
35 plate with a fluorescent plate reader at 540, 550, and 560 nm.
- 36 4. Calculate the optical density (OD) of reduced cytochrome C using the path-length-
37 corrected values: $OD_{550nm} - (OD_{540nm} + OD_{560nm})/2$.
- 38 5. Subtract OD from that of identical samples containing SOD. Covert to $O_2^{\bullet-}$ concen-
39 tration using the extinction coefficient equation of $Em_{550nm} = 2.1 \times 10^4 M/cm$.

01 **3.2. Detection of Hydrogen Peroxide**

02 3.2.1. DCF Fluorescent Assay (See **Note 9**)

- 03 1. Culture endothelial cells or vascular smooth muscle cells on 100-mm Petri dishes.
- 04 2. Aspirate media, rinse cells with PBS, and load cells or vessel segments with freshly
- 05 prepared DCFH-DA (30 μ M) for 15 min to allow intracellular conversion of DCFH
- 06 prior to stimulation with desired agonists.
- 07 3. At the end of incubation, gently scrape cells off dish in 1 ml ice-cold PBS,
- 08 load 200 μ l cell suspensions ($\sim 2 \times 10^5$ cells) into 96-well plate, and read with a
- 09 fluorescent plate reader at excitation and emission wavelengths of 475 and 525 nm,
- 10 respectively.
- 11

12 3.2.2. Amplex Red Assay (See **Note 10**)

- 13 1. Culture endothelial cells or vascular smooth muscle cells on P100 Petri dishes or
- 14 prepare three vessel segments of 2 mm size.
- 15 2. Incubate cells or vessel segments in Krebs Ringer phosphate-glucose buffer (see
- 16 manufacturer's manual) containing 100 μ M Amplex Red and 1 U/ml horseradish
- 17 peroxidase at 37 °C for 30 min, with or without desired agonists.
- 18 3. At end of incubation, transfer 200 μ l post-incubation buffers into 96-well plate and
- 19 read with a fluorescent plate reader at excitation and emission wavelengths of 530
- 20 and 580 nm, respectively.
- 21 4. Generate calibration curve using resorufin standard supplied by the manufacturer.
- 22

23 **3.3. Detection of Nitric Oxide Radical**

24 3.3.1. NO[•]-Specific Microelectrode (See **Notes 11 and 12**)

- 25 26 1. Coat bare carbon fiber electrodes (100 μ m length and 30 μ m outer diameter; Word
- 27 Precision Instruments) with nafion and *o*-PD. Coat with freshly made *o*-PD solution
- 28 at constant potential (+0.9 V vs. Ag/AgCl reference electrode) for 45 min. Dip in
- 29 nafion solution for 3 s and dry for 5 min at 85 °C. The nafion-coating cycle should
- 30 be repeated 10–15 times.
- 31 2. Culture endothelial cells on 35-mm dishes or prepare fresh tissue samples in freshly
- 32 made modified Kreb's/HEPES buffer.
- 33 3. Place the electrode tip at the surface of an individual cell, endocardium, or lumen
- 34 of blood vessels, and then withdraw precisely 5 μ m.
- 35 4. Record NO[•]-dependent oxidation currents (voltage clamp mode, hold at 0.65 V,
- 36 approximately the voltage for peak NO[•] oxidation) immediately after addition of
- 37 agonists using an Axopatch 200B amplifier (Axon Instruments). A silver/silver
- 38 chloride reference electrode is used. Use pCLAMP 7.0 program (Axon Instruments)
- 39 for delivery of voltage protocols and data acquisition and analysis.

- 01 5. Calculate NO^\bullet concentrations from a standard curve obtained using dilutions of
02 de-oxygenated, saturated NO^\bullet gas solutions.

03

04 **3.3.2. Iron-DETC Protocol for Intracellular Trapping of NO^\bullet**
05 **(See Notes 13 and 14)**

- 06 1. Culture endothelial cells on 100-mm Petri dishes or prepare vascular segments
07 (6–12 2-mm vessel segments).
08 2. Bubble freshly prepared saline (0.9% NaCl) with nitrogen gas to remove oxygen.
09 3. Aspirate media and rinse cells with warm PBS once, add 1.5 ml modified
10 Krebs's/HEPES buffer with or without desired agonists, then mix $\text{Fe}^{2+}(\text{DETC})_2$,
11 and immediately add to culture dish (500 μl of each solution, final
12 volume 2.0 ml).
13 4. Incubate in cell culture incubator for desired period for cumulative trapping of NO^\bullet .
14 5. Aspirate buffer, gently collect cells into a 1-ml insulin syringe, snap freeze in
15 liquid nitrogen, then transfer sample column into a finger dewer, and capture
16 $\text{Fe}^{2+}(\text{DETC})_2\text{-NO}^\bullet$ signal using ESR at the following settings:

17 Bruker EMX: Field sweep, 160 G; microwave frequency, 9.39 GHz;
18 microwave power, 10 MW; modulation amplitude, 3 G; conversion time,
19 2621 ms; time constant, 328 ms; modulation amplitude, 3 G; receiver gain,
20 1×10^4 ; and four scans.

21 Miniscope 200: Biofield, 3267; field sweep, 100 G; microwave frequency,
22 9.78 GHz; microwave power, 40 mW; modulation amplitude, 10 G; 4096 points
23 resolution; and receiver gain, 900.

25 **3.3.2.1. IRON-MGD PROTOCOL FOR EXTRACELLULAR TRAPPING OF NO^\bullet**
26 **(See Notes 15 and 16)**

- 27 1. Culture endothelial cells on 100-mm Petri dishes or prepare vascular segments
28 (6–12 2-mm vessel segments).
29 2. Bubble freshly prepared saline (0.9% NaCl) with nitrogen gas to remove oxygen,
30 and then make stock solutions of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 4 mM, and MGD, 20 mM.
31 3. Prepare stock solutions of Fe^{2+}MGD by mixing FeSO_4 and MGD at the ratio of
32 1:5 or 1:10 (final Fe concentration: 0.5 mM).
33 4. Aspirate media and rinse cells with warm PBS once, add 1.5 ml modified
34 Krebs's/HEPES buffer with or without desired agonists, then mix $\text{Fe}^{2+}(\text{MGD})_2$, and
35 immediately add to culture dish.
36 5. Incubate in cell culture incubator for desired period for cumulative trapping of NO^\bullet .
37 6. Collect 1 ml of post-incubation supernatant into a 1-ml insulin syringe and snap freeze
38 in liquid nitrogen, then transfer sample column into a finger dewer, and capture
39 $\text{Fe}^{2+}\text{MGD-NO}^\bullet$ signal using ESR settings as described above for $\text{Fe}^{2+}(\text{DETC})_2$.

4. Notes

1. DHE is cell permeable, which allows intracellular detection of $O_2^{\bullet-}$. It is relatively specific with minimal potential of being oxidized by H_2O_2 or other reactive oxygen species (30). It is very sensitive (fluorescent detection with HPLC identifies as low as 1 pmol/mg protein $O_2^{\bullet-}$, see protocol below) (11) and generally reproducible. The procedure is convenient to use as an initial screening for $O_2^{\bullet-}$ production from both cells and tissues. Results from this widely used $O_2^{\bullet-}$ -detection method have been confirmed by recent ESR studies that unequivocally identify and quantify individual reactive oxygen species. For example, aortic $O_2^{\bullet-}$ production was found to be increased in angiotensin II-induced hypertension using Lucigenin (31) or DHE assays (32), and this was recently confirmed by ESR $O_2^{\bullet-}$ trapping with the $O_2^{\bullet-}$ -specific spin trap cyclic hydroxylamine (16).
2. DHE staining is semi-quantitative. It was demonstrated that DHE can be oxidized by excessive cytochrome C (when the molar ratio of cytochrome C to DHE is > 10) (30,33) or other heme-containing proteins such as hemoglobin (33). Thus, caution should be used when interpreting DHE data in cases where apoptosis or mitochondrial damage is involved or post-hemorrhage endothelium is studied. To minimize influences of this non-specific reaction on data analysis, it is recommended to use cell permeable SOD such as polyethylene glycol-conjugated SOD (Sigma-Aldrich) in parallel and only compare responses that are SOD inhibitable. Another caution is *not* to use lower wavelengths of 490–495/580–600 nm (34). Recent studies demonstrated that peroxidase-catalyzed oxidation of DHE by H_2O_2 produced fluorescent products detectable at the abovementioned wavelengths (34). Using 520/610 nm could potentially avoid these non-specific overlapping fluorescent signals caused by H_2O_2 . In many cases, researchers have to use the wavelengths with which the microscope is equipped, and this may have caused variations in data reporting.
3. DHE–HPLC provides quantitative, sensitive, and specific detection of $O_2^{\bullet-}$ from vascular cells and tissues. Fink and colleagues (11) have shown that the specific HPLC peak for oxyethidium is completely preventable by SOD but is not formed in response to H_2O_2 or peroxynitrite.
4. Modestly larger amounts of biological materials are needed compared to fluorescent imaging of DHE (i.e., three 2-mm aortic rings are required for HPLC assay of DHE compared to only one 2-mm ring for fluorescent microscope). This is, however, a minimal disadvantage considering the quantitative nature of the HPLC-based assay.
5. ESR spin trapping of $O_2^{\bullet-}$ has been proven to selectively detect $O_2^{\bullet-}$ from cultured vascular cells or tissue homogenates in the low nanomolar range (16,18). Our unpublished data suggest that this method is also applicable to intact, isolated blood vessels, but a slightly larger capillary and fitting holder is required to accommodate vessel segments inside the ESR cavity. In addition, cyclic hydroxylamine compounds can be injected into mice for *in vivo* detection of $O_2^{\bullet-}$, but the preferential tissue distribution patterns of these compounds remains unclear (35,36).

- 01 6. CMH is cell permeable and more suitable for detection of intracellular $O_2^{\bullet-}$. CPH,
02 however, is used for extracellular detection of $O_2^{\bullet-}$. The advantage of the spin
03 traps is that the ESR spectrum of the radical spin traps works as a “finger print” of
04 the trapped radical. The problem, however, deals with the limited stability of the
05 radical adducts. Even relatively stable $O_2^{\bullet-}$ adducts of DMPO and DEPMPO can be
06 decomposed by intracellular peroxidases into the corresponding hydroxyl adducts
07 (**Fig. 3**). In case of cyclic hydroxylamines, though very stable when forming
08 adducts with $O_2^{\bullet-}$, they can also trap peroxynitrite to form identical nitroxides (**15**),
09 limiting specificity. Thus, it is highly recommended that only the SOD-inhibitable
10 fraction of the ESR signals is compared between experimental groups.
- 11 7. Because cytochrome C is cell impermeant, this assay provides quantitative
12 detection of *extracellular* $O_2^{\bullet-}$.
- 13 8. Reduced cytochrome C can be oxidized by peroxidases or oxidants such as H_2O_2
14 and peroxynitrite (**8,37**). This will underestimate the rate of production of $O_2^{\bullet-}$.
15 Our own experience suggests that the reproducibility is not great, and the assay is
16 not sensitive enough to detect the low levels of $O_2^{\bullet-}$ found in vascular cells. As
17 cytochrome C is also strictly cell *impermeable*, it is more applicable to activated
18 neutrophils where $O_2^{\bullet-}$ is produced in large quantities extracellularly. It is likely that
19 some intracellular $O_2^{\bullet-}$ can be transported through membrane pores to extracellular
20 space. However, as regulation of this process is poorly understood, it is difficult
21 to predict the intracellular $O_2^{\bullet-}$ production rate based on cytochrome C data.
22 Nevertheless, the cytochrome C assay can be used as a secondary method for $O_2^{\bullet-}$
23 detection in conjunction with another more sensitive method for intracellular $O_2^{\bullet-}$
24 to estimate overall bioactive $O_2^{\bullet-}$.
- 25 9. This assay can be used for intracellular detection of H_2O_2 and is relatively specific.
26 DCF assay is only semi-quantitative, because it is difficult to generate a standard
27 curve that mimics the intracellular situation. In the past, we attempted to add
28 esterases to *ex vivo* incubation of DCFH-DA, but this was not sufficient to
29 produce optimal concentration-absorbance curves when serial dilutions of standard
30 were used. It is unclear whether other enzymes besides esterases are involved in
31 converting DCFH-DA intracellularly. Earlier work by LeBel et al. (**38**) demon-
32 strated that DCF is not oxidized by hydroxyl radical or $O_2^{\bullet-}$ directly, although
33 it can also be oxidized by peroxynitrite (**39**). Similar to $O_2^{\bullet-}$ assays, it is always
34 recommended to use cell-permeable catalase (i.e., polyethylene glycol-conjugated
35 catalase from Sigma-Aldrich) and compare only the catalase-inhibitable signal,
36 because DCF reacts with other cellular peroxides and can redox cycle (**40**). Never-
37 theless, the DCF assay can be used for relative comparison among different
38 experimental groups.
- 39 10. The Amplex Red assay is good for specific, extracellular detection of H_2O_2
and is also quantitative. Recent studies using this method have demonstrated
basal endothelial H_2O_2 production at the rate of 30 pmol/mg protein/min (**17,27**).
However, this assay may not accurately reflect intracellular formation of H_2O_2

- 01 although H_2O_2 is expected to diffuse to the outside of the cell to reach equilibrium.
02 It is unclear how much H_2O_2 is able to diffuse out of the cell, considering presence
03 of intracellular catalase and small thiols that are capable of “trapping” H_2O_2 intra-
04 cellularly. The activities of these H_2O_2 -consuming enzymes or small molecules
05 may change with agonist treatment to compound the capability of the assay to
06 reflect actual H_2O_2 production rate.
- 07 11. Control experiments showed that nafion and *o*-PD coatings effectively eliminated
08 electrode responsiveness to other oxidizable species, including nitrate, nitrite, and
09 H_2O_2 . This method is not only specific and quantitative, it also offers “real-time”
10 monitoring of NO^\bullet production over a time course that has particular utility for
11 signal transduction studies examining temporal and spatial activation of NO^\bullet -
12 producing pathways.
- 13 12. This assay requires an entire patch-clamp electrophysiology setup. It only detects
14 NO^\bullet from released from single endothelial cell or the most surrounding few
15 endothelial cells. This is because NO^\bullet has limited diffusion ability to reach the
16 electrode in the in vitro system. It may not reflect overall NO^\bullet production very
17 accurately.
- 18 13. Several advantages exist for NO^\bullet detection using ESR and
19 $\text{Fe}^{2+}(\text{DETC})_2$. $\text{Fe}^{2+}(\text{DETC})_2$ is specific for bioactive NO^\bullet and does not detect nitrite
20 or nitrate. In addition, the stability of the $\text{Fe}^{2+}(\text{DETC})_2\text{-NO}^\bullet$ complex allows for
21 measurement of the cumulative amount of bioactive NO^\bullet produced over time.
- 22 14. Limitations of this technique include the special handling required for
23 $\text{Fe}^{2+}(\text{DETC})_2$ colloid to prevent oxidation. In addition, $\text{Fe}^{2+}(\text{DETC})_2\text{-NO}^\bullet$ can be
24 oxidized by extracellular H_2O_2 or $\text{O}_2^{\bullet-}$ to form the ESR silent, $\text{Fe}^{3+}(\text{DETC})_2\text{-NO}^\bullet$.
25 However, our data showed that bolus addition of $100\ \mu\text{mol/l}$ H_2O_2 or the same
26 amount of $\text{O}_2^{\bullet-}$ generated by xanthine oxidase decreased the $\text{Fe}^{2+}(\text{DETC})_2\text{-NO}^\bullet$
27 signal by 20%. Both H_2O_2 and $\text{O}_2^{\bullet-}$ caused line broadening of the ESR spectra
28 due to accumulation of Fe^{3+} in the samples. The effect of the line broadening on
29 the quantification of NO^\bullet can be avoided by double integration of the ESR signal
30 of $\text{Fe}^{2+}(\text{DETC})_2\text{-NO}^\bullet$.
- 31 15. Fe^{2+}MGD stays in the extracellular compartment and thus allows detection of NO^\bullet
32 that is diffused out the of endothelial cells. It may thus reflect amount of NO^\bullet that
33 is available to travel within intracellular space. However, how much NO^\bullet eventually
34 reaches adjacent vascular smooth muscle cells also depends on extracellular SOD
35 activity in vivo.
- 36 16. It has been previously reported that autoxidation of MGD may cause formation
37 of $\text{O}_2^{\bullet-}$ and H_2O_2 , which may interfere with quantitative detection of NO^\bullet (41). It
38 was also shown that anaerobic solutions of Fe^{2+}MGD can reduce nitrite to NO^\bullet
39 (42). However, this reaction is negligible under normoxic conditions.

Acknowledgments

This work is supported by NIH/NHLBI grants HL077440 and HL081571 American Heart Association Scientist Development Grant (no. 0435189N to H.C.), American Diabetes Association Research Award (H.C.), Career Development Award from the Schweppe Foundation (H.C.), and Start-up Fund from the University of Chicago (H.C.).

References

1. Cai, H., and Harrison, D. G. (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress, *Circ. Res.* **87**, 840–844.
2. Cai, H., Griendling, K. K., and Harrison, D. G. (2003) The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases, *Trends Pharmacol. Sci.* **24**, 471–478.
3. Griendling, K. K., and FitzGerald, G. A. (2003) Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS, *Circulation* **108**, 1912–1916.
4. Griendling, K. K. (2004) Novel NAD(P)H oxidases in the cardiovascular system, *Heart* **90**, 491–493.
5. Jung, O., Marklund, S. L., Geiger, H., Pedrazzini, T., Busse, R., and Brandes, R. P. (2003) Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice, *Circ. Res.* **93**, 622–629.
6. Khatri, J. J., Johnson, C., Magid, R., Lessner, S. M., Laude, K. M., Dikalov, S. I., Harrison, D. G., Sung, H. J., Rong, Y., and Galis, Z. S. (2004) Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma, *Circulation* **109**, 520–525.
7. Yang, H., Roberts, L. J., Shi, M. J., Zhou, L. C., Ballard, B. R., Richardson, A., and Guo, Z. M. (2004) Retardation of atherosclerosis by overexpression of catalase or both Cu/Zn-superoxide dismutase and catalase in mice lacking apolipoprotein E, *Circ. Res.* **95**, 1075–1081.
8. Tarpey, M. M., Wink, D. A., and Grisham, M. B. (2004) Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations, *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **286**, R431–R444.
9. Munzel, T., Afanas'ev, I. B., Kleschyov, A. L., and Harrison, D. G. (2002) Detection of superoxide in vascular tissue, *Arterioscler. Thromb. Vasc. Biol.* **22**, 1761–1768.
10. Zhao, H., Kalivendi, S., Zhang, H., Joseph, J., Nithipatikom, K., Vasquez-Vivar, J., and Kalyanaraman, B. (2003) Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: potential implications in intracellular fluorescence detection of superoxide, *Free Radic. Biol. Med.* **34**, 1359–1368.

- 01 11. Fink, B., Laude, K., McCann, L., Doughan, A., Harrison, D. G., and Dikalov, S.
02 (2004) Detection of intracellular superoxide formation in endothelial cells and
03 intact tissues using dihydroethidium and an HPLC-based, *Am. J. Physiol. Cell*
04 *Physiol.* **287**, C895–902.
- 05 12. Buettner, G. R., and Mason, R. P. (1990) Spin-trapping methods for detecting
06 superoxide and hydroxyl free radicals in vitro and in vivo, *Methods Enzymol.* **186**,
07 127–133.
- 08 13. Villamena, F. A., and Zweier, J. L. (2004) Detection of reactive oxygen and
09 nitrogen species by EPR spin trapping, *Antioxid. Redox Signal.* **6**, 619–629.
- 10 14. Dikalov, S. I., Dikalova, A. E., and Mason, R. P. (2002) Noninvasive diagnostic
11 tool for inflammation-induced oxidative stress using electron spin resonance
12 spectroscopy and an extracellular cyclic hydroxylamine, *Arch. Biochem. Biophys.*
13 **402**, 218–226.
- 14 15. Dikalov, S., Grigor'ev, I. A., Voinov, M., and Bassenge, E. (1998)
15 Detection of superoxide radicals and peroxynitrite by 1-hydroxy-4-phosphonoxy-
16 2,2,6,6-tetramethylpiperidine: quantification of extracellular superoxide radicals
17 formation, *Biochem. Biophys. Res. Commun.* **248**, 211–215.
- 18 16. Landmesser, U., Cai, H., Dikalov, S., McCann, L., Hwang, J., Jo, H.,
19 Holland, S. M., and Harrison, D. G. (2002) Role of p47(phox) in vascular oxidative
20 stress and hypertension caused by angiotensin II, *Hypertension* **40**, 511–515.
- 21 17. McNally, J. S., Davis, M. E., Giddens, D. P., Saha, A., Hwang, J., Dikalov, S.,
22 Jo, H., and Harrison, D. G. (2003) Role of xanthine oxidoreductase and NAD(P)H
23 oxidase in endothelial superoxide production in response to oscillatory shear stress,
24 *Am. J. Physiol. Heart Circ. Physiol.* **285**, H2290–H2297.
- 25 18. Spiekermann, S., Landmesser, U., Dikalov, S., Brecht, M., Gamez, G., Tatge, H.,
26 Reepschlager, N., Hornig, B., Drexler, H., and Harrison, D. G. (2003) Electron spin
27 resonance characterization of vascular xanthine and NAD(P)H oxidase activity in
28 patients with coronary artery disease: relation to endothelium-dependent vasodi-
29 lation, *Circulation* **107**, 1383–1389.
- 30 19. Cai, H. (2005) Hydrogen peroxide regulation of endothelial function: mechanisms,
31 consequences and origins, *Cardiovasc. Res.* **68**, 26–36.
- 32 20. Cai, H. (2005) NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide
33 and vascular disease, *Circ. Res.* **96**, 818–822.
- 34 21. Liu, X., and Zweier, J. L. (2001) A real-time electrochemical technique for
35 measurement of cellular hydrogen peroxide generation and consumption: evalu-
36 ation in human polymorphonuclear leukocytes, *Free Radic. Biol. Med.* **31**,
37 894–901.
- 38 22. Friedemann, M. N., Robinson, S. W., and Gerhardt, G. A. (1996) o-
39 Phenylenediamine-modified carbon fiber electrodes for the detection of nitric
oxide, *Anal. Chem.* **68**, 2621–2628.
23. Cai, H., Li, Z., Goette, A., Mera, F., Honeycutt, C., Feterik, K., Wilcox, J. N.,
Dudley, S. C., Jr., Harrison, D. G., and Langberg, J. J. (2002) Downregulation of

- 01 endocardial nitric oxide synthase expression and nitric oxide production in atrial
02 fibrillation: potential mechanisms for atrial thrombosis and stroke, *Circulation*
03 **106**, 2854–2858.
- 04 24. Vanin, A. F., Huisman, A., and van Faassen, E. E. (2002) Iron dithiocarbamate
05 as spin trap for nitric oxide detection: pitfalls and successes, *Methods Enzymol.*
06 **359**, 27–42.
- 07 25. Komarov, A. M., Wink, D. A., Feelisch, M., and Schmidt, H. H. (2000) Electron-
08 paramagnetic resonance spectroscopy using N-methyl-D-glucamine dithiocar-
09 bamate iron cannot discriminate between nitric oxide and nitroxyl: implications
10 for the detection of reaction products for nitric oxide synthase, *Free Radic. Biol.*
11 *Med.* **28**, 739–742.
- 12 26. Xia, Y., Cardounel, A. J., Vanin, A. F., and Zweier, J. L. (2000) Electron param-
13 agnetic resonance spectroscopy with N-methyl-D-glucamine dithiocarbamate iron
14 complexes distinguishes nitric oxide and nitroxyl anion in a redox-dependent
15 manner: applications in identifying nitrogen monoxide products from nitric oxide
16 synthase, *Free Radic. Biol. Med.* **29**, 793–797.
- 17 27. Cai, H., McNally, J. S., Weber, M., and Harrison, D. G. (2004) Oscillatory
18 shear stress upregulation of endothelial nitric oxide synthase requires intracellular
19 hydrogen peroxide and CaMKII, *J. Mol. Cell Cardiol.* **37**, 121–125.
- 20 28. Kleschyov, A. L., and Munzel, T. (2002) Advanced spin trapping of vascular nitric
21 oxide using colloid iron diethyldithiocarbamate, *Methods Enzymol.* **359**, 42–51.
- 22 29. Cai, H., Li, Z., Dikalov, S., Holland, S. M., Hwang, J., Jo, H., Dudley, S. C., Jr.,
23 and Harrison, D. G. (2002) NAD(P)H oxidase-derived hydrogen peroxide mediates
24 endothelial nitric oxide production in response to angiotensin II, *J. Biol. Chem.*
25 **277**, 48311–48317.
- 26 30. Benov, L., Sztajnberg, L., and Fridovich, I. (1998) Critical evaluation of the use
27 of hydroethidine as a measure of superoxide anion radical, *Free Radic. Biol. Med.*
28 **25**, 826–831.
- 29 31. Rajagopalan, S., Kurz, S., Munzel, T., Tarpey, M., Freeman, B. A., Griending, K. K.,
30 and Harrison, D. G. (1996) Angiotensin II-mediated hypertension in the rat increases
31 vascular superoxide production via membrane NADH/NADPH oxidase activation.
32 Contribution to alterations of vasomotor tone, *J. Clin. Invest.* **97**, 1916–1923.
- 33 32. Rey, F. E., Cifuentes, M. E., Kiarash, A., Quinn, M. T., and Pagano, P. J. (2001)
34 Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular
35 O₂(⁻) and systolic blood pressure in mice, *Circ. Res.* **89**, 408–414.
- 36 33. Papapostolou, I., Patsoukis, N., and Georgiou, C. D. (2004) The fluorescence
37 detection of superoxide radical using hydroethidine could be complicated by the
38 presence of heme proteins, *Anal. Biochem.* **332**, 290–298.
- 39 34. Patsoukis, N., Papapostolou, I., and Georgiou, C. D. (2005) Interference of
non-specific peroxidases in the fluorescence detection of superoxide radical by
hydroethidine oxidation: a new assay for H₂O₂, *Anal. Bioanal. Chem.* **81**,
1065–1072.

- 01 35. Fink, B., Dikalov, S., and Bassenge, E. (2000) A new approach for extracellular
02 spin trapping of nitroglycerin-induced superoxide radicals both in vitro and in
03 vivo, *Free Radic. Biol. Med.* **28**, 121–128.
- 04 36. Kozlov, A. V., Szalay, L., Umar, F., Fink, B., Kropik, K., Nohl, H., Redl, H.,
05 and Bahrami, S. (2003) Epr analysis reveals three tissues responding to endotoxin
06 by increased formation of reactive oxygen and nitrogen species, *Free Radic. Biol.*
07 *Med.* **34**, 1555–1562.
- 08 37. Thomson, L., Trujillo, M., Telleri, R., and Radi, R. (1995) Kinetics of cytochrome
09 c²⁺ oxidation by peroxynitrite: implications for superoxide measurements in nitric
10 oxide-producing biological systems, *Arch. Biochem. Biophys.* **319**, 491–497.
- 11 38. LeBel, C. P., Ischiropoulos, H., and Bondy, S. C. (1992) Evaluation of the probe
12 2', 7'-dichlorofluorescein as an indicator of reactive oxygen species formation and
13 oxidative stress, *Chem. Res. Toxicol.* **5**, 227–231.
- 14 39. Kooy, N. W., Royall, J. A., and Ischiropoulos, H. (1997) Oxidation of 2', 7'-
15 dichlorofluorescein by peroxynitrite, *Free Radic. Res.* **27**, 245–254.
- 16 40. Rota, C., Chignell, C. F., and Mason, R. P. (1999) Evidence for free radical
17 formation during the oxidation of 2'-7'-dichlorofluorescein to the fluorescent dye
18 2'-7'-dichlorofluorescein by horseradish peroxidase: possible implications for
19 oxidative stress measurements, *Free Radic. Biol. Med.* **27**, 873–881.
- 20 41. Tsuchiya, K., Jiang, J. J., Yoshizumi, M., Tamaki, T., Houchi, H., Minakuchi, K.,
21 Fukuzawa, K., and Mason, R. P. (1999) Nitric oxide-forming reactions of the
22 water-soluble nitric oxide spin-trapping agent, MGD, *Free Radic. Biol. Med.* **27**,
23 347–355.
- 24 42. Tsuchiya, K., Yoshizumi, M., Houchi, H., and Mason, R. P. (2000) Nitric
25 oxide-forming reaction between the iron-N-methyl-D-glucamine dithiocarbamate
26 complex and nitrite, *J. Biol. Chem.* **275**, 1551–1556.
- 27
28
29
30
31
32
33
34
35
36
37
38
39